Abstract: Targeted small molecule therapeutics are enabling the scientific community fight against SARS-CoV-2. In this article, some 1,2-diphenyl-1H-benzimidazole derivatives were designed for their COVID-19 inhibitory activity by docking. Ligands (1a-f) to SARS-CoV-2 (PDB ID: 5R82) are docked To identify the hypothetical binding motif of the title compounds using VLifeMDS software by in-silico (molecular docking studies). These findings showed that the binding energy in all active compounds ranged from -29.12 to -79.53 kcal/mol. If compared to the standard -86.52 kcal/mol). Compound code 1b and 1d were found to be potent with a docking score of -79.53 and -64.72 respectively.
